A total of 231 paraffin-embedded renal tissue sections from patients with biopsy-proven iMN collected between June 2008 and August 2013 were examined for renal PLA2R expression.
PLA2R was examined in paraffin-embedded sections using rabbit polyclonal anti-PLA2R1 antibodies (Sigma, USA) at a dilution of 1:500 after microwaving at 100% power for a total of 18 min, followed by donkey anti-rabbit FITC IgG (Millipore, USA) at a dilution of 1:100.
Two hundred and thirty-one paraffin-embedded renal tissue sections from patients with histology diagnosis of iMN were tested for PLA2R [Figure 1].
Baseline clinical data at kidney biopsy were available for 186 of these 231 patients, including 145 renal PLA2R positive patients and 41 negative patients as summarized in [Table 1].
A total of 149 patients were followed up for more than 12 months after biopsy, including 128 positive and 21 negative in renal PLA2R staining.
30 May 2014 - US FDA said yesterday it had authorised Euroimmun US Inc's Anti-
PLA2R IFA blood test to help identify if membranous glomerulonephritis (MGN), a specific type of kidney disease, is due to the body's rejection of its own kidney tissue or due to another cause.
